Bioresorbable vascular scaffolds: Design, clinical trials, and current applications

Coronary Artery Disease

Volumn 27, Issue 2, 2016, Pages 151-158

  Devito, Fiorella ^a   Zito, Annapaola ^a   Dachille, Annamaria ^a   Carbonara, Rosa ^a   Giardinelli, Francesco ^a   Bulzis, Gabriella ^a   Navarese, Eliano P ^c,d,e   Scicchitano, Pietro ^a   Gaglione, Antonio ^b   Masi, Filippo ^a   Ciccone, Marco M ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d Systematic Investigation and Research on Interventions and Outcomes MEDICINE Research Network   (Germany)

^e Cochrane Heart Group ^*  (United Kingdom)

Author keywords

Bioresorbable vascular scaffold; Drug eluting stent; Optical coherence tomography

Indexed keywords

ARTICLE; BIORESORBABLE SCAFFOLD; CLINICAL EFFECTIVENESS; DEVICE SAFETY; DRUG ELUTING STENT; HUMAN; IN-STENT RESTENOSIS; INFLAMMATION; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; TECHNOLOGY; THROMBOSIS; BIODEGRADABLE IMPLANT; BLOOD VESSEL PROSTHESIS; CORONARY ARTERY DISEASE; DEVICES; PERCUTANEOUS CORONARY INTERVENTION; PROCEDURES; RESTENOSIS; TISSUE SCAFFOLD;

ABSORBABLE IMPLANTS; BLOOD VESSEL PROSTHESIS; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; TISSUE SCAFFOLDS;

EID: 84957847110     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0000000000000339     Document Type: Article

References (50)

1. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1978; 1:263.
2. Serruys PW, Keane D. The bailout stent. Is a friend in need always a friend indeed? Circulation 1993; 88 (Pt 1):2455-2457.
3. Navarese EP, Kowalewski M, Kandzari D, Lansky A, Górny B, Kołtowski L, et al. First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. Open Heart 2014; 1: e000064.
4. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007; 115:2435-2441.
5. Navarese EP, Tandjung K, Claessen B, Andreotti F, Kowalewski M, Kandzari DE, et al. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ 2013; 347:f6530.
6. Oberhauser JP, Hossainy S, Rapoza RJ. Design principles and performance of bioresorbable polymeric vascular scaffolds. EuroIntervention 2009; 5 (Suppl):F15-F22.
7. Campos CM, Muramatsu T, Iqbal J, Zhang YJ, Onuma Y, Garcia-Garcia HM, et al. Bioresorbable drug-eluting magnesium-alloy scaffold for treatment of coronary artery disease. Int J Mol Sci 2013; 14:24492-24500.
8. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008; 371:899-907.
9. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009; 373:897-910.
10. Khattab AA, Windecker S. Vascular restoration therapy: what should the clinical and angiographic measures for success be? EuroIntervention 2009; 5:F49-F53.
11. Onuma Y, Serruys PW, Perkins LE, Okamura T, Gonzalo N, García-García HM, et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 2010; 122:2288-2300.
12. Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 2010; 122:2301-2312.
13. Gonzalo N, Barlis P, Serruys PW, Garcia-Garcia HM, Onuma Y, Ligthart J, Regar E. Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction than in drug-eluting stents implanted for stable/unstable angina: insights from optical coherence tomography. JACC Cardiovasc Interv 2009; 2:445-452.
14. Jiang WW, Su SH, Eberhart RC, Tang L. Phagocyte responses to degradable polymers. J Biomed Mater Res A 2007; 82:492-497.
15. Gomez-Lara J, Brugaletta S, Farooq V, Onuma Y, Diletti R, Windecker S, et al. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography. JACC Cardiovasc Interv 2011; 4:1271-1280.
16. Brugaletta S, Heo JH, Garcia-Garcia HM, Farooq V, van Geuns RJ, de Bruyne B, et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? Eur Heart J 2012; 33:1325-1333.
17. Gutiérrez-Chico JL, van Geuns RJ, Regar E, van der Giessen WJ, Kelbæk H, Saunamäki K, et al. Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial. Eur Heart J 2011; 32:2454-2463.
18. Bourantas CV, Garcia-Garcia HM, Campos CA, Zhang YJ, Muramatsu T, Morel MA, et al. Implications of a bioresorbable vascular scaffold implantation on vessel wall strain of the treated and the adjacent segments. Int J Cardiovasc Imaging 2014; 30:477-484.
19. Brugaletta S, Gogas BD, Garcia-Garcia HM, Farooq V, Girasis C, Heo JH, et al. Vascular compliance changes of the coronary vessel wall after bioresorbable vascular scaffold implantation in the treated and adjacent segments. Circ J 2012; 76:1616-1623.
20. Bourantas CV, Farooq V, Zhang Y, Muramatsu T, Gogas BD, Thuesen L, et al. Circumferential distribution of the neointima at six-month and two-year follow-up after a bioresorbable vascular scaffold implantation: a substudy of the ABSORB Cohort B Clinical Trial. EuroIntervention 2015; 10:1299-1306.
21. Kraak RP, Hassell ME, Grundeken MJ, Koch KT, Henriques JP, Piek JJ, et al. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry. EuroIntervention 2015; 10:1160-1168.
22. Rzeszutko Ł, Siudak Z, Włodarczak A, Lekston A, Depukat R, Ochała A, et al. Contemporary use of bioresorbable vascular scaffolds (BVS) in patients with stable angina and acute coronary syndromes. Polish National Registry. Kardio Pol 2014; 72:1394-1399.
23. Diletti R, Farooq V, Girasis C, Bourantas C, Onuma Y, Heo JH, et al. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Heart 2013; 99:98-105.
24. Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2015; 10:1144-1153.
25. Muramatsu T, Onuma Y, van Geuns RJ, Chevalier B, Patel TM, Seth A, et al. ABSORB Cohort B Investigators; ABSORB EXTEND Investigators; SPIRIT FIRST Investigators; SPIRIT II Investigators; SPIRIT III Investigators; SPIRIT IV Investigators. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials. JACC Cardiovasc Interv 2014; 7:482-493.
26. Abizaid A, Ribamar Costa J Jr, Bartorelli AL, Whitbourn R, van Geuns RJ, Chevalier B, et al. ABSORB EXTEND investigators. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention 2015; 10:1396-1401.
27. Brugaletta S, Gori T, Low AF, Tousek P, Pinar E, Gomez-Lara J, et al. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). JACC Cardiovasc Interv 2015; 8 (Pt B):189-197.
28. Erratum in: JACC Cardiovasc Interv 2015; 8:503.
29. Cortese B, Ielasi A, Romagnoli E, Varricchio A, Cuculo A, Loi B, et al. Clinical comparison with short-term follow-up of bioresorbable vascular scaffold versus everolimus-eluting stent in primary percutaneous coronary interventions. Am J Cardiol 2015; 116:705-710.
30. Verheye S, Ormiston JA, Stewart J, Webster M, Sanidas E, Costa R, et al. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6-and 12-month clinical and multimodality imaging results. JACC Cardiovasc Interv 2014; 7:89-99.
31. Waksman R, Pakala R, Kuchulakanti PK, Baffour R, Hellinga D, Seabron R, et al. Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. Catheter Cardiovasc Interv 2006; 68:607-617. discussion 618-609.
32. Haude M, Ince H, Abizaid A, Toelg R, Lemos PA, von Birgelen C, et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. Lancet 2015 [Epub ahead of print].
33. Brown AJ, McCormick LM, Braganza DM, Bennett MR, Hoole SP, West NE. Expansion and malapposition characteristics after bioresorbable vascular scaffold implantation. Catheter Cardiovasc Interv 2014; 84:37-45.
34. Seth A, Ravisekar V, Kaul U. Use of 'Guideliner' catheter to overcome failure of delivery of Absorb™ Bioresorbable Vascular Scaffold in calcified tortuous coronary lesions: technical considerations in 'Real World Patients'. Indian Heart J 2014; 66:453-458.
35. D-avík V, Colombo A. The absorb bioresorbable vascular scaffold in coronary bifurcations: insights from bench testing. JACC Cardiovasc Interv 2014; 7:81-88.
36. Seth A, Sengottuvelu G, Ravisekar V. Salvage of side branch by provisional 'TAP technique' using Absorb™ bioresorbable vascular scaffolds for bifurcation lesions: first case reports with technical considerations. Catheter Cardiovasc Interv 2014; 84:55-61.
37. Grundeken MJ, Hassell ME, Kraak RP, de Bruin DM, Koch KT, Henriques JP, et al. Treatment of coronary bifurcation lesions with the Absorb bioresorbable vascular scaffold in combination with the Tryton dedicated coronary bifurcation stent: evaluation using two-and three-dimensional optical coherence tomography. EuroIntervention 2014 [Epub ahead of print].
38. Bourantas CV, Serruys PW, Nakatani S, Zhang YJ, Farooq V, Diletti R, et al. Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data. EuroIntervention 2015; 11:746-756.
39. Allahwala UK, Cockburn JA, Shaw E, Figtree GA, Hansen PS, Bhindi R. Clinical utility of optical coherence tomography (OCT) in the optimisation of Absorb bioresorbable vascular scaffold deployment during percutaneous coronary intervention. EuroIntervention 2015; 10:1154-1159.
40. Indolfi C, Mongiardo A, Spaccarotella C, Caiazzo G, Torella D, De Rosa S. Neointimal proliferation is associated with clinical restenosis 2 years after fully bioresorbable vascular scaffold implantation. Circ Cardiovasc Imaging 2014; 7:755-757.
41. Ormiston JA, Serruys PW, Onuma Y, van Geuns RJ, de Bruyne B, Dudek D, et al. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circ Cardiovasc Interv 2012; 5:620-632.
42. Rivero F, Benedicto A, Bastante T, Cuesta J, Diego G, Alfonso F. Subacute thrombosis of a bioresorbable vascular scaffold implanted for recurrent in-stent restenosis. EuroIntervention 2015; 11:780.
43. Ruiz-Salmerón RJ, Pereira S, de Araujo D. Bioresorbable vascular scaffold collapse causes subacute thrombosis. J Invasive Cardiol 2014; 26: E98-E99.
44. Miyazaki T, Panoulas VF, Sato K, Naganuma T, Latib A, Colombo A. Acute stent thrombosis of a bioresorbable vascular scaffold implanted for ST-segment elevation myocardial infarction. Int J Cardiol 2014; 174:e72-e74.
45. Ho HH, Er Ching M, Ong PJ, Ooi YW. Subacute bioresorbable vascular scaffold thrombosis: a report of 2 cases. Heart Vessels 2015; 30:545-548.
46. Arroyo D, Togni M, Puricel S, Gerard B, Sonja L, Corpataux N, et al. Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial. Trials 2014; 15:9.
47. Jaguszewski M, Ghadri JR, Zipponi M, Bataiosu DR, Diekmann J, Geyer V, et al. Feasibility of second-generation bioresorbable vascular scaffold implantation in complex anatomical and clinical scenarios. Clin Res Cardiol 2015; 104:124-135.
48. Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, et al. ABSORB III Investigators. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med 2015; 373:1905-1915.
49. Karanasos A, van Geuns RJ, Zijlstra F, Regar E. Very late bioresorbable scaffold thrombosis after discontinuation of dual antiplatelet therapy. Eur Heart J 2014; 35:1 781.
50. Yahagi K, Virmani R, Kesavamoorthy B. Very late scaffold thrombosis of everolimus-eluting bioresorbable scaffold following implantation in STEMI after discontinuation of dual antiplatelet therapy. Cardiovasc Interv Ther 2015 [Epub ahead of print].